CINECA IRIS Institutional Research Information System

BORGHETTI, ALBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.501
NA - Nord America 1.964
SA - Sud America 280
EU - Europa 229
Continente sconosciuto - Info sul continente non disponibili 157
AF - Africa 30
OC - Oceania 1
Totale 5.162
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.912
CN - Cina 1.338
SG - Singapore 536
HK - Hong Kong 311
BR - Brasile 227
VN - Vietnam 119
IT - Italia 78
KR - Corea 57
FI - Finlandia 35
JP - Giappone 31
CA - Canada 23
IN - India 22
GB - Regno Unito 20
DE - Germania 19
BD - Bangladesh 18
AR - Argentina 15
AT - Austria 13
MX - Messico 13
CO - Colombia 11
FR - Francia 11
RU - Federazione Russa 11
MA - Marocco 9
IQ - Iraq 8
NL - Olanda 8
EC - Ecuador 7
PH - Filippine 7
SA - Arabia Saudita 7
ZA - Sudafrica 7
CL - Cile 6
PK - Pakistan 6
TR - Turchia 6
VE - Venezuela 6
ES - Italia 5
AZ - Azerbaigian 4
ID - Indonesia 4
KE - Kenya 4
LT - Lituania 4
PL - Polonia 4
SE - Svezia 4
AE - Emirati Arabi Uniti 3
CH - Svizzera 3
KZ - Kazakistan 3
PE - Perù 3
PY - Paraguay 3
TH - Thailandia 3
TN - Tunisia 3
TT - Trinidad e Tobago 3
UA - Ucraina 3
UZ - Uzbekistan 3
BM - Bermuda 2
BS - Bahamas 2
CR - Costa Rica 2
ET - Etiopia 2
IE - Irlanda 2
JM - Giamaica 2
LB - Libano 2
MY - Malesia 2
NI - Nicaragua 2
OM - Oman 2
AO - Angola 1
AU - Australia 1
BE - Belgio 1
CW - ???statistics.table.value.countryCode.CW??? 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
GE - Georgia 1
HR - Croazia 1
HU - Ungheria 1
IL - Israele 1
IR - Iran 1
IS - Islanda 1
JO - Giordania 1
KG - Kirghizistan 1
LV - Lettonia 1
MZ - Mozambico 1
NP - Nepal 1
PA - Panama 1
PR - Porto Rico 1
PS - Palestinian Territory 1
PT - Portogallo 1
RW - Ruanda 1
SK - Slovacchia (Repubblica Slovacca) 1
SR - Suriname 1
TM - Turkmenistan 1
TW - Taiwan 1
UG - Uganda 1
UY - Uruguay 1
Totale 5.006
Salva come PNG Salva come JPEG
Città #
Shanghai 1.111
Hong Kong 310
Singapore 303
San Jose 296
Santa Clara 223
Ashburn 100
Boardman 100
Council Bluffs 89
Hefei 85
Seoul 57
Los Angeles 46
Ho Chi Minh City 45
Helsinki 30
Tokyo 30
Chicago 29
Hanoi 27
Atlanta 26
Dallas 22
São Paulo 22
Beijing 21
New York 19
Phoenix 15
Nuremberg 14
Redondo Beach 14
Buffalo 13
Florence 13
Rome 11
Baltimore 9
Rio de Janeiro 9
Lauterbourg 8
Brasília 7
Guarulhos 6
Haiphong 6
Mexico City 6
Milan 6
Montreal 6
Orem 6
Belo Horizonte 5
Brooklyn 5
Houston 5
Salt Lake City 5
Wuhan 5
Baku 4
Chennai 4
Columbus 4
Frankfurt am Main 4
Guangzhou 4
Jeddah 4
Lappeenranta 4
Memphis 4
Miami 4
Osasco 4
Pisa 4
Porto Alegre 4
San Francisco 4
Santiago 4
Secaucus 4
Tampa 4
Thái Bình 4
Toronto 4
Warsaw 4
Amsterdam 3
Bogotá 3
Bologna 3
Bắc Ninh 3
Canoas 3
Casablanca 3
Cleveland 3
Curitiba 3
Denver 3
Dhaka 3
Hamilton 3
Hyderabad 3
Indianapolis 3
Las Vegas 3
London 3
Lucca 3
Manchester 3
Medellín 3
Misterbianco 3
Nairobi 3
Philadelphia 3
Queens 3
Quito 3
Ribeirão Preto 3
Riverside 3
Stockholm 3
Tashkent 3
Vienna 3
Washington 3
Addis Ababa 2
Ankara 2
Asunción 2
Baghdad 2
Barranquilla 2
Betim 2
Blumenau 2
Cao Lanh 2
Cape Town 2
Capão da Canoa 2
Totale 3.348
Salva come PNG Salva come JPEG
Nome #
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients 487
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial 268
Treatment of Aorto-iliac and Infrainguinal Vascular Infections with a Prefabricated Bovine Pericardial Graft 225
Appropriateness of virological monitoring with long-acting injectable cabotegravir and rilpivirine 218
Letter to the Editor: Real-Life Experience of Long-Acting Cabotegravir–Rilpivirine Combination in a Person Living with HIV with Detectable Viremia: A Case Report 199
Liver fibrosis is associated with cognitive impairment in HIV-positive patients 171
SARS-CoV-2 infection in a highly experienced person living with HIV 113
Integrase inhibitors use and cmv infection predict immune recovery in people living with hiv starting first-line therapy 91
Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study 87
No significant changes in body fat mass in virologically suppressed, HIV- positive patients switched to lamivudine-dolutegravir 81
Cardiovascular disease risk in a cohort of virologically-suppressed PLWHIV switching to doravirine: preliminary data from the real life 73
Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line 72
Shall We Dance? Extending TANGO's Results to Clinical Practice 69
Off-label use of tocilizumab in patients with SARS-CoV-2 infection 69
Short Communication: Efficacy and Safety of Dolutegravir Plus Lamivudine as a First-Line Regimen in Clinical Practice 67
Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Rome, Italy during the COVID-19 Outbreak 62
HIV and vicarious stigma in a cohort of people living with HIV in Italy: What happens when the stigma is fueled by healthcare providers? 59
Lung ultrasonography for early management of patients with respiratory symptoms during COVID-19 pandemic 58
Autochthonous dengue outbreak in Rome, Italy, in 2023 57
Toxoplasmosis mimicking CMV chorioretinitis in newly diagnosed PLWH: a case report 56
Characteristics of mental health interventions in a cohort of Italian PLWH over the last five years: impact of HIV disease and outbreak of COVID-19 pandemic 54
Experienced PLWH switching to DOR/3TC/TDF in outpatient setting: real-word data on tolerability and Cost Savings from an Italian multicenter cohort 52
Efficacy and Tollerability of INI-Based 2-Drug Regimen in Virosuppressed Persons Living with HIV: A Systematic Review and Meta-Analysis 52
Investigating seroprevalence of IgG antibodies against Monkeypox Virus (MPXV) in a cohort of people living with HIV (PLWH) in Rome, during the 2022 outbreak: Moving beyond traditional at-risk populations 49
Cohort profile: the observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE) 49
Cardiovascular Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in Virologically Suppressed PLWHIV: A Comparative Analysis of CVD Scores 48
Clinical presentation of human monkeypox virus infection during the 2022 outbreak: descriptive case series from a large italian Research Hospital 47
Changes in Metabolic Profile in PLWHIV Switching to Doravirine-Based Regimen 47
Comparing the long-term effectiveness and safety of dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide fumarate as first-line regimens: a real life multicentre cohort 46
Differences in the Long-term Impact of the COVID-19 Pandemic on the Mental Health and Professional Quality of Life of Resident and Specialist Physicians 45
The association between stigma and wellbeing in an Italian cohort of PLWH: The role of social support and personal factors 45
How do I manage disseminated Mycobacterium avium complex disease in people with HIV? 44
Efficacy of Lamivudine Plus Dolutegravir vs Dolutegravir-Based 3-Drug Regimens in People With HIV Who Are Virologically Suppressed 44
New insight of human-IgH 3′regulatory regions in immunoglobulins switch 39
Blood telomere length gain in people living with HIV switching to dolutegravir plus lamivudine versus continuing triple regimen: a longitudinal, prospective, matched, controlled study 38
Association between contralateral background parenchymal enhancement on MRI and outcome in patients with unilateral invasive breast cancer breast receiving neoadjuvant chemotherapy 37
Are we really ready for dual therapy in naive people with HIV? The experience from a large university hospital in Rome, Italy 35
Virological outcomes with dolutegravir plus either lamivudine or two NRTIs as switch strategies: a multi-cohort study 33
Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy 32
Use of telehealth for HIV care in Italy: Are doctors and patients on the same page? A cross-sectional study 32
Lamivudine-based maintenance antiretroviral therapies in patients living with HIV-1 with suppressed HIV RNA: derivation of a predictive score for virological failure 30
Focal status epilepticus as unique clinical feature of COVID-19: A case report 29
Transmitted drug resistance to NRTIs and risk of virological failure in naïve patients treated with integrase inhibitors 29
Psychological distress during the initial stage of the COVID-19 pandemic in an Italian population living with HIV: an online survey 28
Use of Long-Acting Therapies for HIV Care in Italy: Are People Living with HIV Prepared for Change? A Cross-Sectional Study 28
Are we ready for long-acting? A feasibility evaluation of long-acting cabotegravir-rilpivirine in clinical practice 27
Functional associations between polymorphic regions of the human 3'IgH locus and COVID-19 disease 27
Virological efficacy of dual therapy with lamivudine and dolutegravir in HIV-1-infected virologically suppressed patients: long-term data from clinical practice 27
Reduced soluble CD14 levels after switching from a dual regimen with lamivudine plus boosted protease inhibitors to lamivudine plus dolutegravir in virologically suppressed HIV-infected patients 27
Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study 27
Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients During Lamivudine Plus Dolutegravir Maintenance Therapy in Clinical Practice 26
Older Age is Associated with Higher Dolutegravir Exposure in Plasma and Cerebrospinal Fluid of People Living with HIV. 26
Liver fibrosis is associated with cognitive impairment in people living with HIV 26
Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication 26
Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy 25
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 24
Ophthalmic artery resistance index IS increased in HIV-Infected patients and is influenced by protease inhibitors exposure 24
Implementing a Personalized Antimicrobial Stewardship Program for Women with Gynecological Cancers and Healthcare-Associated Infections 24
Is it time to re-think the use of etravirine in patients with available genotypic resistance test? 24
Evolution of cellular HIV DNA levels in virologically suppressed patients switching to dolutegravir/lamivudine versus maintaining a triple regimen: a prospective, longitudinal, matched, controlled study 24
People Living with HIV in the COVID-19 Era: A Case Report. 24
Atlas-M Study Group. Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 23
Short Communication: Comparing Lamivudine+Dolutegravir and Bictegravir/Emtricitabine/Tenofovir Alafenamide as Switch Strategies: Preliminary Results from Clinical Practice 23
Kaposi-like manifestations in a newly diagnosed AIDS transgendered patient with silicone embolism syndrome and disseminated tuberculosis 23
Difference in the neurocognitive functions of WLWH and MLWH in an Italian cohort of people living with HIV. 23
Older Age is Associated with Higher Dolutegravir Exposure in Plasma and Cerebrospinal Fluid of People Living with HIV 22
Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting 22
Impact of NRTI resistance mutations on virological effectiveness of antiretroviral regimens containing elvitegravir: a multi-cohort study 22
COVID-19 diagnosis does not rule out other concomitant diseases 22
Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort StudyImpact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based 22
An outbreak of acute hepatitis A among young adult men: clinical features and HIV coinfection rate from a large teaching hospital in Rome, Italy 22
The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study 22
Psychological distress during the initial stage of the COVID-19 pandemic in an Italian population living with HIV: an online survey 21
Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: preliminary results from clinical practice. 21
Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients 21
The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study 21
Infections in hospitalised patients affected by end-stage diseases: a narrative overview 21
Prevalence of osteoporosis and predictors of low BMD in a cohort of HIV-1-infected patients in Rome: features of a population at high risk 20
Two-Drug Regimen Containing Darunavir: Metabolic Evaluation of an Old Dual Therapy 20
Impact of the COVID-19 Pandemic on Health Care Is Negatively Associated With Psychosocial Well-Being in an Italian Cohort of People Living With HIV 20
Impact of Antiretroviral Therapy on the Risk of Recurrence in HIV-1 Infected Patients with Kaposi Sarcoma: A Multicenter Cohort Experience 20
Determinants of SARS-COV-2 seroconversion in a cohort of recovered patients 20
Early use of tecovirimat in a young man with severe mpox skin lesions: a case report 20
Dolutegravir Plus Lamivudine as First-Line Regimen in a Multicenter Cohort of HIV-1-Infected Patients: Preliminary Data from Clinical Practice 19
'How much raltegravir do you take?' The answer may not be so obvious: an accidental finding from clinical practice 19
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 19
Trends of hospitalisations rates in a cohort of HIV-infected persons followed in an Italian hospital from 1998 to 2016 19
Risk of Tumor Onset in HIV+ Patients on Two-Drug Regimens: A Cohort Study in an Italian Hospital 19
Dolutegravir plus lamivudine for the treatment of HIV-1 infection 19
Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: a multicenter retrospective cohort study from 2007 to 2015 19
An outbreak of acute hepatitis A among young adult men: clinical features and HIV coinfection rate from a large teaching hospital in Rome, Italy 19
HIV DNA Decay in a Treatment-Naive Patient Starting Dolutegravir Plus Lamivudine with Resistance Mutations to Integrase Inhibitors: A Case Report 18
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 18
Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients 18
SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV 18
ATLAS-M Study Group . Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy 18
Long-Term Serological Response to 13-Valent Pneumococcal Conjugate Vaccine Versus 23-Valent Polysaccharide Vaccine in HIV-Infected Adults 18
HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART 17
Nasopharingeal bacterial and fungal colonization in HIV-positive versus HIV-negative adults 17
The Role of Prior HBV Infection on the Efficacy of 3TC/DTG as a Maintenance Therapy 17
Totale 4.784
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.339
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.339
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/2024132 0 0 0 0 0 99 0 6 1 3 0 23
2024/20252.498 2 99 123 4 114 168 1.139 74 67 171 165 372
2025/20261.603 62 264 149 152 147 72 251 127 127 137 85 30
2026/2027929 80 570 279 0 0 0 0 0 0 0 0 0
Totale 5.162